China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited
Your view on CSWYY
Overview
What the company does, where it operates, and who runs it.
About China Shineway Pharmaceutical Group Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Zhenjiang Li
- Headquarters
- No. 168 Shiluan Street, Shijiazhuang, CN
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Zhenjiang Li
- Headquarters
- No. 168 Shiluan Street, Shijiazhuang, CN
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong.
The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products.
The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for China Shineway Pharmaceutical Group Limited, and the rating behind it. CSWYY last traded at $19.25, 6.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for China Shineway Pharmaceutical Group Limited. Starting points for China Shineway Pharmaceutical Group Limited: P/E 6.5, EPS $21.13, beta 0.88 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for China Shineway Pharmaceutical Group Limited. China Shineway Pharmaceutical Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for China Shineway Pharmaceutical Group Limited. Trailing twelve-month EPS for China Shineway Pharmaceutical Group Limited stands at $21.13. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for China Shineway Pharmaceutical Group Limited. China Shineway Pharmaceutical Group Limited has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
China Shineway Pharmaceutical Group Limited valued side by side against its closest peers. China Shineway Pharmaceutical Group Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold China Shineway Pharmaceutical Group Limited, and how their positions are changing. At a $36.4M market value, institutional positions materially move China Shineway Pharmaceutical Group Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by China Shineway Pharmaceutical Group Limited executives and directors. Shares of China Shineway Pharmaceutical Group Limited have traded between $18.53 and $22.54 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming China Shineway Pharmaceutical Group Limited. China Shineway Pharmaceutical Group Limited is a $36.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming China Shineway Pharmaceutical Group Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for China Shineway Pharmaceutical Group Limited. Coverage tracks China Shineway Pharmaceutical Group Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.